global glp-1 obesity drug market size forecast 2030 Oral Drugs and 2035 GLP-1 Market Trends and Global

Patience pays off: slow, steady qualification across a handful of low-volatility options can be more reliable than sprinting through high-risk choices

In the literature, I dont think that there is a strong association as of yet, but clinically we are definitely seeing a lot of patients in practice either with telogen effluvium or androgenetic alopecia, which we do believe is somehow being caused by the use of these medications, Nusbaum said

This effect is most pronounced with short-acting agents such as exenatide twice daily and becomes attenuated (though not eliminated) with longer-acting formulations

Published studies suggest the magnitude of effect in obesity cohorts may be larger with triple agonism at top doses, though head-to-head laboratory comparisons are still emerging in the published record

funding acquisition, J.R.-Q